Once again, Novo's semaglutide shows cardiovascular benefit, weight loss — this time in adults with heart failure
Novo Nordisk’s GLP-1 Wegovy has shown cardiovascular benefit again, this time in the Phase III STEP HFpEF trial, on top of the expected weight loss, the company announced at the European Society of Cardiology (ESC) Congress today.
Against placebo, 2.4 mg of Wegovy (semaglutide) showed “large” reductions in heart failure-related symptoms and physical limitations, as well as improvements in exercise function and weight loss in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.